SCHEMBL480256

SCHEMBL480256

COC(=O)c1cccc(NC(=O)c2ccc(C(C)C(O)(c3ccnc(Cl)c3)C(F)(F)F)c(Cl)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
BTK Q06187 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
HTR1F P30939 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
MAPK14 Q16539 1/20 0.34
NPC1 O15118 3/20 0.34
TP53 P04637 3/20 0.34
MAPT P10636 3/20 0.34
RAB9A P51151 2/20 0.34
GRM4 Q14833 1/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479936 0.92 SMN1; SMN2 (0.36) GRM5ALDH1A1KMT2ABTKSMN1; SMN2
SCHEMBL753188 0.92 SMN1; SMN2 (0.36) GRM5ALDH1A1KMT2ABTKSMN1; SMN2
SCHEMBL752900 0.87 PDK1 (0.39) KMT2AMEN1BTKSMN1; SMN2NPC1
SCHEMBL479642 0.87 PDK1 (0.39) KMT2AMEN1BTKSMN1; SMN2NPC1
SCHEMBL15789688 0.87 GRM5 (0.36) GRM5ALDH1A1KMT2AMEN1BTK
SCHEMBL754762 0.86 RAB9A (0.50) KMT2AMEN1POLBSMN1; SMN2NPC1
SCHEMBL479972 0.86 RAB9A (0.50) KMT2AMEN1POLBSMN1; SMN2NPC1
SCHEMBL480861 0.85 MAPT (0.44) ALDH1A1KMT2AMEN1POLBSMN1; SMN2
SCHEMBL480160 0.85 PDK1 (0.43) ALDH1A1SMN1; SMN2MAPK14CYP1A2CYP2C19
SCHEMBL479727 0.83 RAB9A (0.42) KMT2AMEN1SMN1; SMN2NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411361-B1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-06-18 EP disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2411361-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-02-01 EP disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 GRM5 197/4885ALDH1A1 317/4885KMT2A 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.